Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lyndra Therapeutics Announces Positive Data from Phase 3 Study of Weekly Oral Risperidone
Details : LYN-005 (oral weekly risperidone), is being evaluated in phase 3 clinical trials for the treatment of people living with schizophrenia and bipolar 1 disorder.
Brand Name : LYN-005
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2024
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : $30.0 million
Deal Type : Financing
Sun Pharma to Acquire 16.7% Stake in Lyndra Therapeutics for $30 mn
Details : The financing will obtain access to technology for certain compounds while developing novel pharmaceutical delivery systems, including LYN-005 (risperidone) for schizophrenia and bipolar I disorder.
Brand Name : LYN-005
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : $30.0 million
Deal Type : Financing
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Sarissa Capital
Deal Size : $101.0 million
Deal Type : Series E Financing
Lyndra Therapeutics Raises US$101 Million in Series E Funding
Details : The net proceeds will support the development of Lyndra’s pipeline, including oral weekly LYN-005 (risperidone), which is near completion of a pivotal phase 3 study and is being developed for the treatment of people living with schizophrenia and bipola...
Brand Name : LYN-005
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 25, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Sarissa Capital
Deal Size : $101.0 million
Deal Type : Series E Financing
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DLP-114 is an investigational therapy that employs Delpor's proprietary technology platform. It is placed sub-dermally to provide continuous and consistent dosing of risperidone for schizophrenia maintenance therapy lasting 6-12 months.
Brand Name : DLP-114
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Oral weekly LYN-005 (risperidone) is a serotonin and norepinephrine reuptake inhibitor and is being developed for the treatment of people living with schizophrenia and bipolar I disorder.
Brand Name : LYN-005
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 09, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Uzedy (risperidone) is a dopamine type 2 (D2) and serotonin type 2 (5HT2) receptor antagonist. It is indicated for the treatment of schizophrenia in adults.
Brand Name : Uzedy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Luye Pharma’s Rykindo® for the Treatment of Schizophrenia and Bipolar 1 Disorder
Details : Rykindo® (risperidone) is an atypical antipsychotic for the treatment of schizophrenia anfd as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. It acts as combined D2 and 5HT2 re...
Brand Name : Rykindo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 15, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : European Investment Bank
Deal Size : $41.8 million
Deal Type : Agreement
Details : TV-46000 is a long-acting subcutaneous antipsychotic that uses a novel copolymer drug delivery technology in combination with a well-characterized molecule, risperidone, that is in clinical development as a treatment for schizophrenia.
Brand Name : TV-46000
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : European Investment Bank
Deal Size : $41.8 million
Deal Type : Agreement
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Uzedy, a risperidone subcutaneous Long-Acting Injectable (LAI) for the maintenance treatment of schizophrenia using MedinCell’s proprietary technology.
Brand Name : Uzedy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2022
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Assia Chemical Industries Ltd
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : mdc-IRM, (risperidone) extended-release injectable suspension for the treatment of patients with schizophrenia (Teva codename: TV-46000), is the most advanced investigational product based on MedinCell’s BEPO® technology.
Brand Name : mdc-IRM
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 03, 2022
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Assia Chemical Industries Ltd
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?